$MVIS

MicroVision to report Q3FY26 results on October 28, 2026

MicroVision (NASDAQ: MVIS) will report Q3FY26 results on October 28, 2026, with a conference call scheduled. The company's IRIS lidar sensor was selected by Overland AI for its IBEX autonomous vehicle, marking a defense sector expansion. MicroVision reaffirmed FY26 revenue guidance of $10M-$15M and projected doubling in FY27, aiming for $30M. The company expects cost savings and reduced cash burn in 2027, with manufacturing consolidation in Orlando, Florida.

Original reporting
Published Oct 15, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MicroVision to report Q3FY26 results on October 28, 2026 — source image
Decision brief

The 30-second read

$MVISNeutralMed
01

Why it matters

The scheduled Q3 FY26 results and management discussion create a near-term trading catalyst. The article also reiterates FY26 revenue guidance ($10M to $15M) and claims for 2027 revenue doubling plus cost savings and reduced cash burn, which can influence expectations for the upcoming earnings release.

02

Market read

Traders should treat Oct 28 as the key event date for potential expectation resets around revenue trajectory, cash burn reduction, and defense commercialization progress.

03

What to watch

Investors may focus less on the headline FY26 range and more on whether the Overland AI IRIS selection translates into recognized revenue timing, backlog, and manufacturing ramp constraints.

Relevance 5/10Novelty 4/10Timing: Oct 28, 2026 after the market close (results) and 1:30 pm PT/4:30 pm ET call

Background

MicroVision develops lidar perception solutions and is positioning for defense and industrial revenue growth, including an Overland AI IRIS sensor selection for the IBEX autonomous ground vehicle.

Company-level read

Ticker impact

$MVISNeutralMedium confidence
Context

MicroVision (MVIS) schedules its Q3 FY26 results for Oct 28, 2026 after the close, with a same-day management call and webcast.

Expected impact

Likely volatility into the Oct 28 after-close results as investors price in guidance confirmation versus any incremental updates on 2027 growth and cash burn reduction.

Evidence & confidence

The article is a scheduled earnings disclosure plus operational context (FY26 revenue outlook reaffirmed, 2027 growth/cost-savings claims), which can shift expectations even without a new quarter’s datapoint yet.

Market effects

Adds a near-term catalyst for lidar/autonomous-systems sentiment, but does not introduce a sector-wide regulatory or demand shock.

No direct regional macro linkage beyond MicroVision’s Orlando manufacturing consolidation mentioned in the article.

Limited global impact; the defense/automotive lidar angle is company-specific rather than a broad international policy or procurement shift.

Counterpoint

The piece is largely a calendar and reiteration of prior outlook, so price action may be muted unless the Oct 28 report includes materially different cash burn, gross margin, or defense revenue conversion.

Key entities

  • MicroVision, Inc.

    NASDAQ-listed lidar perception solutions provider scheduling Q3 FY26 results for Oct 28, 2026 after the close.

  • Overland AI

    Selected MicroVision’s IRIS long-range lidar sensor for the next-generation IBEX autonomous ground vehicle.

  • IBEX autonomous ground vehicle

    Autonomous vehicle platform integrating MicroVision’s IRIS sensor, described as capable of carrying up to 2,000 pounds and traveling above 35 mph.

Related articles

$MVISHigh

MicroVision (MVIS) Q3 2026 Earnings Call Transcript

MicroVision (MVIS) reported Q3 2026 revenue of $2.4M, up from $0.2M in Q3 2025, with year-to-date revenue at $4.8M. The company expects full-year 2026 revenue of $10M-$15M and aims to double that in 2027. Operating cash burn is targeted at $60M for 2026 and $40M for 2027, with workforce reductions and other cost-cutting measures in place. The company is focused on nondilutive funding sources and strategic partnerships.

$MVISMed

MicroVision Reports Third Quarter 2026 Results with Record Lidar Revenue and Accelerated Path to Profitability

MICROVISION, INC. (MVIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MicroVision Reports Third Quarter 2026 Results with Record Lidar Revenue and Accelerated Path to Profitability Sustained revenue growth, shipping to meet high demand, confidence in 2026 revenue guidance, implemented cost reductions ORLANDO, Fla. – October 28, 2026 –

$FULCMed

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Pricing of $17.0 Million Public Offering

MicroVision (NASDAQ:MVIS) priced a public offering of 6.8 million units at $2.50 per unit, with each unit including one share and one immediately exercisable warrant to buy one share at $2.50, expiring five years after issuance. Gross proceeds are expected at about $17.0 million. Proceeds will fund general corporate purposes, including working capital and capex. Closing is expected around Aug. 17, 2026.

$MVISMedAI 8/10

MicroVision, Inc.: MicroVision Announces Launch of Proposed Public Offering

MicroVision (NASDAQ:MVIS) said it has commenced a proposed public offering of units, each unit consisting of one share of common stock (or a pre-funded warrant in lieu) and one warrant to buy one share. MicroVision will sell the shares and warrants, with final terms to be set at pricing. Net proceeds are for general corporate purposes, including working capital and capex.